$PIRS News Article - Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346) https://marketwirenews.com/news-releases/pier...83196.html
(0)
(0)
Pieris Pharmaceuticals, Inc. (PIRS) Stock Research Links